Kinetics of glucagon in man: effects of starvation.
Journal: 1976/August - Proceedings of the National Academy of Sciences of the United States of America
ISSN: 0027-8424
PUBMED: 1064045
Abstract:
Serum stimulates the production of prostaglandins by transformed mouse fibroblasts. Hydrocortisone (cortisol) inhibits this stimulation. The half-maximal inhibition occurs at 6x10-9 M. Studies with cells labeled with [3H]arachidonic acid in their lipids show that the stimulation by serum results in the release of arachidonic acid from the cellular lipids, mostly phospholipids. Hydrocortisone inhibits this release but does not inhibit the production of prostaglandins from exogenously supplied arachidonic acid. This inhibition of arachidonic acid release from phospholipids may be the mechanism for the anti-inflammatory action of corticosteroids.
Relations:
Content
Citations
(18)
References
(15)
Conditions
(1)
Drugs
(13)
Chemicals
(1)
Organisms
(1)
Processes
(1)
Similar articles
Articles by the same authors
Discussion board
Proc Natl Acad Sci U S A 73(5): 1735-1739

Kinetics of glucagon in man: effects of starvation.

Abstract

Serum stimulates the production of prostaglandins by transformed mouse fibroblasts. Hydrocortisone (cortisol) inhibits this stimulation. The half-maximal inhibition occurs at 6x10-9 M. Studies with cells labeled with [3H]arachidonic acid in their lipids show that the stimulation by serum results in the release of arachidonic acid from the cellular lipids, mostly phospholipids. Hydrocortisone inhibits this release but does not inhibit the production of prostaglandins from exogenously supplied arachidonic acid. This inhibition of arachidonic acid release from phospholipids may be the mechanism for the anti-inflammatory action of corticosteroids.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (914K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Blackard WG, Nelson NC, Andrews SS. Portal and peripheral vein immunoreactive glucagon concentrations after arginine or glucose infusions. Diabetes. 1974 Mar;23(3):199–202. [PubMed] [Google Scholar]
  • Marliss EB, Aoki TT, Unger RH, Soeldner JS, Cahill GF., Jr Glucagon levels and metabolic effects in fasting man. J Clin Invest. 1970 Dec;49(12):2256–2270.[PMC free article] [PubMed] [Google Scholar]
  • Wise JK, Hendler R, Felig P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest. 1973 Nov;52(11):2774–2782.[PMC free article] [PubMed] [Google Scholar]
  • TAIT JF. REVIEW: THE USE OF ISOTOPIC STEROIDS FOR THE MEASUREMENT OF PRODUCTION RATES IN VIVO. J Clin Endocrinol Metab. 1963 Dec;23:1285–1297. [PubMed] [Google Scholar]
  • Sherwin RS, Fisher M, Hendler R, Felig P. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl J Med. 1976 Feb 26;294(9):455–461. [PubMed] [Google Scholar]
  • Genuth SM. Metabolic clearance of insulin in man. Diabetes. 1972 Oct;21(10):1003–1012. [PubMed] [Google Scholar]
  • Sherwin RS, Kramer KJ, Tobin JD, Insel PA, Liljenquist JE, Berman M, Andres R. A model of the kinetics of insulin in man. J Clin Invest. 1974 May;53(5):1481–1492.[PMC free article] [PubMed] [Google Scholar]
  • Liljenquist JE, Bomboy JD, Lewis SB, Sinclair-Smith BC, Felts PW, Lacy WW, Crofford OB, Liddle GW. Effect of glucagon on net splanchnic cyclic AMP production in normal and diabetic men. J Clin Invest. 1974 Jan;53(1):198–204.[PMC free article] [PubMed] [Google Scholar]
  • Felig P, Gusberg R, Hendler R, Gump FE, Kinney JM, Mulrow PJ. Concentrations of glucagon and the insulin:glucagon ratio in the portal and peripheral circulation. Proc Soc Exp Biol Med. 1974 Oct;147(1):88–90. [PubMed] [Google Scholar]
  • Felig P, Wahren J, Hendler R, Brundin T. Splanchnic glucose and amino acid metabolism in obesity. J Clin Invest. 1974 Feb;53(2):582–590.[PMC free article] [PubMed] [Google Scholar]
  • Rocha DM, Santeusanio F, Faloona GR, Unger RH. Abnormal pancreatic alpha-cell function in bacterial infections. N Engl J Med. 1973 Apr 5;288(14):700–703. [PubMed] [Google Scholar]
  • Lindsey A, Santeusanio F, Braaten J, Faloona GR, Unger RH. Pancreatic alpha-cell function in trauma. JAMA. 1974 Feb 18;227(7):757–761. [PubMed] [Google Scholar]
  • Müller WA, Faloona GR, Unger RH. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med. 1973 Jan;54(1):52–57. [PubMed] [Google Scholar]
  • Sherwin RS, Bastl C, Finkelstein FO, Fisher M, Black H, Hendler R, Felig P. Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest. 1976 Mar;57(3):722–731.[PMC free article] [PubMed] [Google Scholar]
  • Felig P. Interaction of insulin and amino acid metabolism in the regulation of gluconeogenesis. Isr J Med Sci. 1972 Mar;8(3):262–270. [PubMed] [Google Scholar]
Abstract
Serum stimulates the production of prostaglandins by transformed mouse fibroblasts. Hydrocortisone (cortisol) inhibits this stimulation. The half-maximal inhibition occurs at 6x10-9 M. Studies with cells labeled with [3H]arachidonic acid in their lipids show that the stimulation by serum results in the release of arachidonic acid from the cellular lipids, mostly phospholipids. Hydrocortisone inhibits this release but does not inhibit the production of prostaglandins from exogenously supplied arachidonic acid. This inhibition of arachidonic acid release from phospholipids may be the mechanism for the anti-inflammatory action of corticosteroids.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.